New strategies for the treatment of hyperkalemia
Authors:
Open Access
- 2 November 2024
- journal article
- review article
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 132, 18-26
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- Physician Perceptions, Attitudes, and Strategies Towards Implementing Guideline-Directed Medical Therapy in Heart Failure with Reduced Ejection Fraction. A Survey of the Heart Failure Association of the ESC and the ESC Council for Cardiology PracticeEuropean Journal of Heart Failure, 2024
- Hyperkalaemia in Cardiological Patients: New Solutions for an Old ProblemCardiovascular Drugs and Therapy, 2024
- Potassium Reduction with Sodium Zirconium Cyclosilicate in Patients with Heart FailureESC Heart Failure, 2022
- An international Delphi consensus regarding best practice recommendations for hyperkalaemia across the cardiorenal spectrumEuropean Journal of Heart Failure, 2022
- Serum Potassium in the PARADIGM-HF TrialEuropean Journal of Heart Failure, 2020
- Patiromer Versus Placebo to Enable Spironolactone Use in Patients with Resistant Hypertension and Chronic Kidney Disease ( AMBER ): Results in the Pre-Specified Subgroup with Heart FailureEuropean Journal of Heart Failure, 2020
- Serum Potassium and Clinical Outcomes in Heart Failure Patients: Results of Risk Calculations in 21 334 Patients in the UKESC Heart Failure, 2019
- Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney DiseaseJAMA, 2015
- Maintenance of Serum Potassium with Sodium Zirconium Cyclosilicate (ZS-9) in Heart Failure Patients: Results from a Phase 3 Randomized, Double-Blind, Placebo-Controlled TrialEuropean Journal of Heart Failure, 2015
- Regulation of potassium (K) handling in the renal collecting ductPflügers Archiv - European Journal of Physiology, 2008